Royalty Pharma (RPRX) Operating Expenses (2019 - 2026)
Royalty Pharma (RPRX) posted Operating Expenses of $67.5 million for Q1 2026, down 71.09% sequentially from $233.6 million in Q4 2025, and up 98.26% YoY from $34.1 million in Q1 2025.
Royalty Pharma (RPRX) Operating Expenses (2019 - 2026) Analysis & Trends
Royalty Pharma has reported Operating Expenses for 8 years, with the latest figure at $67.5 million in Q1 2026.
- Quarterly Operating Expenses rose 98.26% year-over-year to $67.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $852.1 million (up 134.46% YoY) and the FY2025 annual result came in at $818.7 million, down 15.7% from the prior year.
- Operating Expenses eased to $67.5 million in Q1 2026 per RPRX's latest filing, from $233.6 million in the prior quarter.
- Over five years, Operating Expenses peaked at $1.0 billion in Q4 2022 and troughed at -$170.4 million in Q3 2024.
- A 5-year average of $273.5 million and a median of $233.6 million in 2025 frame the typical range for Operating Expenses.
- The widest YoY moves for Operating Expenses: up 1479.41% in 2024, down 144.27% in 2024.
- Over 5 years, Operating Expenses stood at $1.0 billion in 2022, then tumbled by 101.61% to -$16.8 million in 2023, then soared by 1479.41% to $232.1 million in 2024, then increased by 0.64% to $233.6 million in 2025, then slumped by 71.09% to $67.5 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $67.5 million, $233.6 million, and $182.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 367.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 541.02 Mn |
| Mar 31, 2026 | 67.54 Mn |
| Dec 31, 2025 | 233.61 Mn |
| Sep 30, 2025 | 182.14 Mn |
| Jun 30, 2025 | 368.87 Mn |
| Mar 31, 2025 | 34.07 Mn |
| Dec 31, 2024 | 232.13 Mn |
| Sep 30, 2024 | -170.38 Mn |
| Jun 30, 2024 | 267.64 Mn |
| Mar 31, 2024 | 641.75 Mn |
| Dec 31, 2023 | -16.83 Mn |
| Sep 30, 2023 | 384.87 Mn |
| Jun 30, 2023 | 289.36 Mn |
| Mar 31, 2023 | 205.00 Mn |
| Dec 31, 2022 | 1.05 Bn |
| Sep 30, 2022 | 381.25 Mn |
| Jun 30, 2022 | 158.16 Mn |
| Mar 31, 2022 | 342.33 Mn |
| Dec 31, 2021 | 422.28 Mn |
| Sep 30, 2021 | 282.72 Mn |